Pharmacokinetics and pharmacodynamics of hydroxyurea

被引:89
作者
Gwilt, PR
Tracewell, WG
机构
[1] MDS Harris, Lincoln, NE 68502 USA
[2] Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA
关键词
D O I
10.2165/00003088-199834050-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hydroxyurea is used in the treatment of various forms of cancer, sickle-cell anaemia and HIV infection. Oral absorption of the drug is virtually complete, the volume of distribution is equivalent to total body water and elimination is through both renal and nonrenal mechanisms, Nonrenal elimination of hydroxyurea is characterised by Michaelis-Menten kinetics. Further studies are necessary to clarify several aspects of the pharmacokinetics and pharmacodynamics of hydroxyurea: the effect of age and disease state, concentration-effect relationship, the role of therapeutic drug monitoring, and the mechanisms of renal and nonrenal elimination. The recent development of improved assays for hydroxyurea should have benefits for future pharmacokinetic studies.
引用
收藏
页码:347 / 358
页数:12
相关论文
共 82 条
[1]  
ADAMSON RH, 1965, J PHARMACOL EXP THER, V150, P322
[2]   EVIDENCE FOR THE INVOLVEMENT OF CYTOCHROME-P-450-DEPENDENT MONOOXYGENASE(S) IN THE FORMATION OF GENOTOXIC METABOLITES FROM N-HYDROXYUREA [J].
ANDRAE, U .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 118 (02) :409-415
[3]  
ARIEL IM, 1970, CANCER-AM CANCER SOC, V25, P705, DOI 10.1002/1097-0142(197003)25:3<705::AID-CNCR2820250331>3.0.CO
[4]  
2-D
[5]  
BECKLOFF GERALD L., 1965, CANCER CHEMO THERAP REP, V48, P57
[6]  
BELT RJ, 1980, CANCER, V46, P455, DOI 10.1002/1097-0142(19800801)46:3<455::AID-CNCR2820460306>3.0.CO
[7]  
2-N
[8]  
BIRON F, 1995, J ACQ IMMUN DEF SYND, V10, P36
[9]  
BLASBERG RG, 1975, J PHARMACOL EXP THER, V195, P73
[10]  
BLUMENREICH MS, 1993, CANCER, V71, P2828, DOI 10.1002/1097-0142(19930501)71:9<2828::AID-CNCR2820710924>3.0.CO